Search the Studies

58 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
000957-HGA Phase 1/2, Open-Label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 (MMA-101 following administration of SEL-110) in Pediatric Subjects with Mut Subtype Isolated Methylmalonic Acidemia (MMA)Participants currently recruited/enrolled3-17 YearsNHGRIRecurrent
000860-CA Phase I/II Study of Zotiraciclib for Recurrent High-Grade Gliomas with Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) MutationsRecruitment has not started18-125 YearsNCI Recurrent
000628-CA Study of Prospective Monitoring of Subjects with Biochemically Recurrent Prostate Cancer Using 18F-DCFPyLRecruitment has not started18-125 YearsNCI Recurrent
000580-CA Phase 1/2, Open Label Dose-Escalation and Expansion Trial of Nkt2152, an Orally Administered Hif2a Inhibitor, to Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Recurrent
000484-CRandomized Phase II Trial of Durvalumab (D) plus Olaparib (O) and Cediranib (C: DOC) Compared to OC or DC or Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer with Prior BevacizumabParticipants currently recruited/enrolled18-125 YearsNCI Recurrent
000462-CPhase 2, Open-label, Single-arm, Window of Opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients With Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Recurrent
000324-CPhase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesParticipants currently recruited/enrolled3-35 YearsNCI Recurrent
000317-CA Phase II, Open-Label Trial of PT-112 in Subjects with Thymoma and Thymic CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Recurrent
000206-CHEndometrial Basis for Infertility in Women with Recurrent Implantation Failure and Pregnancy LossParticipants currently recruited/enrolled18-42 YearsNICHDRecurrent
000096-CA Phase II study of Immunotherapy Combination: Irradiated PD-L1 CAR-NK cells plus Pembrolizumab plus N-803 for Subjects with Recurrent/Metastatic Gastric or Head and Neck CancerParticipants currently recruited/enrolled18-125 YearsNCI Recurrent
000030-CPhase 2 Study of Bintrafusp alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).Participants currently recruited/enrolled18-125 YearsNCI Recurrent
22-C-0005Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung CancerParticipants currently recruited/enrolled18-125 YearsNCI Recurrent
22-C-0003Feasibility of Evaluating Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral MicrodialysisParticipants currently recruited/enrolled18-39 YearsNCI Recurrent
21-C-0013A Phase I/II Study of Adjuvant PRGN-2012 in Adult Patients with Recurrent Respiratory PapillomatosisParticipants currently recruited/enrolled18-125 YearsNCI Recurrent
20-C-0097A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects with Thymoma and Thymic CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Recurrent
20-C-0069A First-In-Human Phase I Single-Agent Dose-Escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsParticipants currently recruited/enrolled18-125 YearsNCI Recurrent
20-C-0010Phase II Trial of Radium-223 in Biochemically Recurrent Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI Recurrent
19-C-0117A Phase 1 / 2 Single Arm Open-label Clinical Trial of Gavocabtagene Autoleucel (gavo-cel) in Patients with Advanced Mesothelin Expressing CancerParticipants currently recruited/enrolled18-125 YearsNCI Recurrent
19-C-0041Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)Participants currently recruited/enrolled18-125 YearsNCI Recurrent
18-C-0110Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell CancersParticipants currently recruited/enrolled18-125 YearsNCI Recurrent
18-C-0059Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesParticipants currently recruited/enrolled3-39 YearsNCI Recurrent
18-C-0034A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI Recurrent
18-C-0005Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI Recurrent
17-C-0175CC-4047-BRN-001: A Phase 2 Clinical Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults with Recurrent or Progressive Primary Brain TumorsCompleted Study; data analyses ongoing3-20 YearsNCI Recurrent
17-C-0153Phase I Trial of Image Guided Focally Dose Escalated Prostate SBRT for Locally Recurrent Prostate Cancer after Prior RadiotherapyParticipants currently recruited/enrolled18-125 YearsNCI Recurrent
17-C-010918F-DCFPyL PET/CT in High Risk and Recurrent Prostate CancerEnrolling by Invitation18-125 YearsNCI Recurrent
17-C-0102Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS CancersParticipants currently recruited/enrolled18-99 YearsNCI Recurrent
17-C-0061Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid CancerCompleted Study; data analyses ongoing18-125 YearsNCI Recurrent
17-C-0037Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent GlioblastomaParticipants currently recruited/enrolled18-125 YearsNCI Recurrent
17-C-0011Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerCompleted Study; data analyses ongoing18-125 YearsNCI Recurrent
17-C-0009Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) plus Temozolomide versus Temozolomide alone in Adults with Recurrent Anaplastic Astrocytoma and GlioblastomaCompleted Study; data analyses ongoing18-125 YearsNCI Recurrent
16-I-0165An open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 (leniolisib) in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/p110 delta-activating mutatNo longer recruiting/follow-up only12-75 YearsNIAIDRecurrent
16-C-0088A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary PeritoneaCompleted Study; data analyses ongoing18-125 YearsNCI Recurrent
16-C-0081A Phase I Dose Escalation Trial of Re-Irradiation in Good Prognosis Recurrent GlioblastomaNo longer recruiting/follow-up only18-125 YearsNCI Recurrent
16-C-0073A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian CancerCompleted Study; data analyses ongoing18-125 YearsNCI Recurrent
16-C-0035Prostvac in Patients with Biochemically Recurrent Prostate CancerNo longer recruiting/follow-up only18-125 YearsNCI Recurrent
16-C-0034A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior BevacizumabCompleted Study; data analyses ongoing18-125 YearsNCI Recurrent
16-C-0011A Phase I-II Trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade GliomasCompleted Study; data analyses ongoing18-125 YearsNCI Recurrent
16-C-0009Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center TrialCompleted Study; data analyses ongoing18-125 YearsNCI Recurrent
15-C-0205Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients with Clinically Localized Prostate Cancer Undergoing Active SurveillanceCompleted Study; data analyses ongoing18-99 YearsNCI Recurrent
15-C-0145Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination with Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersParticipants currently recruited/enrolled18-125 YearsNCI Recurrent
15-C-0029Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell MalignanciesParticipants currently recruited/enrolled3-39 YearsNCI Recurrent
14-C-0001Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/ParagangliomaCompleted Study; data analyses ongoing18-125 YearsNCI Recurrent
13-C-0095A Phase 2 Study of GI-6207 in Patients with Recurrent Medullary Thyroid CancerCompleted Study; data analyses ongoing18-125 YearsNCI Recurrent
12-C-0081Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast CancerNo longer recruiting/follow-up only18-125 YearsNCI Recurrent
10-I-0216Studies of Disorders with Increased Susceptibility to Fungal InfectionsParticipants currently recruited/enrolled0-125 YearsNIAIDRecurrent
10-C-0174Related and Unrelated Donor Hematopoietic Stem Cell Transplant for DOCK8 DeficiencyParticipants currently recruited/enrolled4-125 YearsNCI Recurrent
10-C-0054Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells from the Original Transplant Donor to Patients with Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell TransplantationNo longer recruiting/follow-up only18-75 YearsNCI Recurrent
09-I-0184Studies in the Pathogenesis of Systemic Capillary Leak SyndromeParticipants currently recruited/enrolled0-125 YearsNIAIDRecurrent
08-I-0184Studies in the Pathogenesis of AnaphylaxisParticipants currently recruited/enrolled13-75 YearsNIAIDRecurrent
07-I-0033Screening Protocol for Detection and Characterization of Infections and Infection SusceptibilityParticipants currently recruited/enrolled0-125 YearsNIAIDRecurrent
06-H-0190Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders with Alemtuzumab (Campath)Completed Study; data analyses ongoing18-85 YearsNHLBIRecurrent
05-I-0213Screening and Baseline Assessment of Patients with Abnormalities of Immune FunctionParticipants currently recruited/enrolled0-125 YearsNIAIDRecurrent
01-I-0202Natural History, Genetics, Phenotype, and Treatment of Mycobacterial InfectionsParticipants currently recruited/enrolled0-100 YearsNIAIDRecurrent
00-I-0159Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)Participants currently recruited/enrolled0-125 YearsNIAIDRecurrent
00-HG-0153Investigations into Chediak-Higashi Syndrome and Related DisordersParticipants currently recruited/enrolled0-70 YearsNHGRIRecurrent
93-I-0119Detection and Characterization of Host Defense DefectsParticipants currently recruited/enrolled0-125 YearsNIAIDRecurrent
81-M-0126The Evaluation of Women with Menstrually Regulated Mood and Behavioral DisordersParticipants currently recruited/enrolled18-50 YearsNIMH Recurrent